ROR2 promotes invasion and chemoresistance of triple-negative breast cancer cells by activating PI3K/AKT/mTOR signaling
Oncology Research · 2024
DOI: 10.32604/or.2024.045433 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2024. Verfasst von Xia DA und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thyroid, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Receptor Tyrosine Kinase-like Orphan Receptors, TOR Serine-Threonine Kinases, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast and Thyroid, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
- Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
- Department of Pathology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Zitieren
APA
DA, X., Ge, H., Shi, J., Zhu, C., Wang, G., Fang, Y., & Xu, J. (2024). ROR2 promotes invasion and chemoresistance of triple-negative breast cancer cells by activating PI3K/AKT/mTOR signaling. Oncology Research. https://doi.org/10.32604/or.2024.045433
Vancouver
DA X, Ge H, Shi J, Zhu C, Wang G, Fang Y, et al. ROR2 promotes invasion and chemoresistance of triple-negative breast cancer cells by activating PI3K/AKT/mTOR signaling. Oncology Research. 2024. doi:10.32604/or.2024.045433
BibTeX
@article{DA2024,
author = {DA, Xia and Ge, Han and Shi, Junfeng and Zhu, Chunhua and Wang, Guozhu and Fang, Yuan and Xu, Jin},
title = {ROR2 promotes invasion and chemoresistance of triple-negative breast cancer cells by activating PI3K/AKT/mTOR signaling},
journal = {Oncology Research},
year = {2024},
doi = {10.32604/or.2024.045433}
}
EUVIMED